MedTrace Logo

Perioperative Evaluation of Terlipressin Infusion During Living Donor Liver Transplantation on Incidence of Acute Kidney

NCT02059460 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2016-12-15

No results posted yet for this study

Summary

To study the impact of intra and post-operative Terlipressin infusion on the occurrence of acute kidney injury after LDLT To investigate perioperative Neutrophil Gelatinase Associated Lipocalin (NGAL) changes and study the effect of Terlipressin on NGAL blood levels

Conditions

Interventions

DRUG

Terlipressin

Terlipressin (Glypressin®) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively

DRUG

placebo

Sponsors & Collaborators

  • Dr. Mohamed Helmi Ibrahim Afifi

    collaborator UNKNOWN

  • Dr. Khaled Ahmed Yassen

    collaborator UNKNOWN

  • Dr. Khalid Mousa Abouelenain

    collaborator UNKNOWN

  • Dr. Mohamed Abdelrauf kandil

    collaborator UNKNOWN

  • Dr. Ayman Alsebaey Qotb Alghoraieb.

    collaborator UNKNOWN

  • National Liver Institute, Egypt

    lead OTHER

Principal Investigators

  • Hanaa S Rashed, MSc · National Liver Institute, Egypt

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Egypt

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02059460 on ClinicalTrials.gov